Try our beta test site
73 studies found for:    cabozantinib OR XL184
Show Display Options
Rank Status Study
1 Active, not recruiting Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
Conditions: NF1;   Neurofibromatosis;   Plexiform Neurofibromas
Intervention: Drug: Cabozantinib
2 Active, not recruiting A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Condition: Prostate Cancer
Intervention: Drug: Cabozantinib
3 Completed Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
Conditions: Solid Tumors;   Cancer;   NSCLC
Interventions: Drug: cabozantinib capsules;   Drug: cabozantinib tablets
4 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Placebo tablets
5 Terminated
Has Results
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
Condition: Prostate Cancer Metastatic
Intervention: Drug: Cabozantinib
6 Completed
Has Results
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma of the Extrahepatic Bile Duct
Intervention: Drug: Cabozantinib
7 Active, not recruiting A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Cabozantinib tablets;   Drug: Everolimus (Afinitor) tablets
8 Recruiting Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: Panitumumab;   Drug: Cabozantinib
9 Completed XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Condition: Multiple Myeloma
Intervention: Drug: Cabozantinib
10 Completed Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
Conditions: Healthy;   Hepatic Impairment
Intervention: Drug: cabozantinib
11 Completed Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
Conditions: Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions: Drug: cabozantinib;   Drug: prednisone
12 Active, not recruiting Cabozantinib in Advanced Solid Malignancies
Conditions: Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
13 Completed A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Conditions: Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Huerthle Cell Thyroid Cancer;   Renal Cell Carcinoma
Interventions: Drug: rosiglitazone;   Drug: XL184
14 Completed
Has Results
Cabozantinib for Metastatic Triple Negative BrCa
Condition: Breast Cancer
Intervention: Drug: Cabozantinib
15 Completed Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Intervention: Drug: Cabozantinib (XL184)
16 Recruiting Cabozantinib for Malignant Pheochromocytoma
Condition: Neuroendocrine Tumors
Interventions: Drug: Cabozantinib;   Behavioral: Questionnaire
17 Active, not recruiting A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: CABOZANTINIB;   Drug: gemcitabine
18 Completed Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
Conditions: Lymphoma;   Cancer;   Thyroid Carcinoma
Intervention: Drug: XL184
19 Completed Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Condition: Astrocytic Tumors
Intervention: Drug: XL184
20 Active, not recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.